ArcticZymes Technologies ASA
AZT.OL
Get informed when a big investor buys or sells
+ FollowMarket Cap$1B
Close$
$18.96
3.5% downside
Current Fair Value
3.5% downsideOvervalued by 3.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.00 Billion |
|---|---|
| Enterprise Value | $831.76 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.19 |
| Beta | 0.57 |
| Outstanding Shares | 51,071,390 |
Return
| Return on Equity | 4.61% |
|---|---|
| Return on Assets | 4.22% |
| Return on Invested Capital | 3.20% |
Valuation & Multiples
| P/E Ratio | 65.2 |
|---|---|
| PEG | 108.81 |
| Price to Sales | 9.83 |
| Price to Book Ratio | 3.28 |
| Enterprise Value to Revenue | 6.59 |
| Enterprise Value to EBIT | 71.85 |
| Enterprise Value to Net Income | 51 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$33.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$33.30 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ArcticZymes Technologies ASA
54 employees
CEO: Michael Benjamin Akoh ArcticZymes Technologies ASA is a leading life sciences firm dedicated to the development, production, and global sale of recombinant enzymes. These specialized enzymes are essential for a variety of applications, including molecular res...